Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus

NCT00927953 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT00927953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00927953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus
Lead sponsor
MacroGenics
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2009
Completion date
May 31, 2011
Enrollment
13 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute flaccid paralysis, encephalitis, meningitis, west nile fever, west nile neuroinvasive disease, west nile virus infection